The clinical effectiveness and cost-effectiveness of brief intervention for excessive alcohol consumption among people attending sexual health clinics: a randomised controlled trial (SHEAR)

Mike J Crawford,1* Rahil Sanatinia,1 Barbara Barrett,2 Sarah Byford,2 Madeleine Dean,1 John Green,3 Rachael Jones,4 Baptiste Leurent,5 Anne Lingford-Hughes,6 Michael Sweeting,7 Robin Touquet,8 Peter Tyrer1 and Helen Ward9

1Centre for Mental Health, Imperial College London, London, UK
2Centre for the Economics of Mental and Physical Health, The King’s College London, London, UK
3Central and North West London NHS Foundation Trust, London, UK
4Chelsea and Westminster Hospital NHS Foundation Trust, London, UK
5PRIMENT Clinical Trials Unit, University College, London, UK
6Centre for Neuropsychopharmacology, Imperial College London, London, UK
7Medical Research Council (MRC) Biostatistics Unit, Cambridge, UK
8Imperial College NHS Foundation Trust, London, UK
9School of Public Health, Imperial College London, London, UK

*Corresponding author

Declared competing interests of authors: All authors have completed the unified competing interest form (available on request from the corresponding author). ALH has undertaken a consultancy for Lundbeck International Neuroscience Foundation, has applied for grants for support for brain scans from GlaxoSmithKline (GSK), pending from Lundbeck, and has received payment for lectures from the Lundbeck Institute, UK, Janssen, Pfizer and Servier. ALH was paid by Lundbeck for travel expenses to attend an international meeting. RJ has received payment (including travel expenses) for lectures for non-promotional educational tools devised for various producers of antiretroviral agents. Institutions for all authors have received funding from the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme for other studies. MJC, RS, BB, SB, MD, JG, BL, MS, RT, PT and HW declare no other interests.

Published May 2014
DOI: 10.3310/hta18300
Scientific summary

Sexual Health and Excessive Alcohol: Randomised trial
Health Technology Assessment 2014; Vol. 18: No. 30
DOI: 10.3310/hta18300

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Scientific summary

Background

Concerns have been expressed about high levels of alcohol consumption among people attending sexual health clinics. Cross-sectional surveys have repeatedly demonstrated that a high proportion of people attending these clinics are drinking above recommended levels. It has been reported that those who drink excessively are more likely to be diagnosed with a sexually transmitted infection (STI). Brief intervention for excessive alcohol consumption has been shown to be effective across a range of medical settings, but there is very little evidence about its impact when offered to people attending sexual health clinics. The effects of brief intervention for excessive alcohol consumption on sexual health outcomes have not been examined and cost-effectiveness of this approach is unknown.

Objectives

We aimed to examine the clinical effectiveness and cost-effectiveness of opportunistic brief intervention for excessive alcohol use among people who attend sexual health clinics. To achieve this aim we:

- examined whether or not brief intervention reduced subsequent alcohol consumption measured 6 months later compared with control treatment
- examined whether or not brief intervention compared with control treatment was associated with changes in sexual behaviour
- examined the cost-effectiveness of brief intervention compared with control treatment.

Methods

Study design

The study was a single-blind, parallel-group, randomised controlled trial.

Participants

Study participants were recruited from three sexual health clinics in central and west London. To take part in the study, potential participants had to be aged 19 years or above, be drinking excessively according to the Modified-Single Alcohol Screening Question and be willing to provide written informed consent. We excluded any person who was unable to communicate in English sufficiently well to complete baseline questionnaires, anyone who did not have an address or contact telephone number and anyone who believed they may not have been contactable again 6 months later.

Main outcome measures

All outcomes were measured 6 months after randomisation and assessed behaviour in the 3 months prior to the date of the assessment. The primary outcome was mean weekly alcohol consumption (measured using the Form 90) and the main secondary outcome was the proportion of participants who reported any unprotected sex during the previous 3 months. Secondary outcomes were mean units of alcohol consumed per drinking day and percentage days abstinent (both measured using the Form 90); whether or not the participant was drinking excessively; total number of sexual partners; number of unprotected sexual partners; any incidence of regretted sex; any incidence of unprotected sex after drinking alcohol or while drunk; how long they knew their last sexual partner before they had sex with them; unplanned pregnancy; and any new diagnosis of a STI. Finally we collected data on health-related quality of life.
(measured using the European Quality of Life-5 Dimensions scale), and resource use during the past 6 months measured using a modified version of the Adult Service Use Schedule.

**Study procedures**

On days when recruitment took place, clinic staff gave all those attending the service a postcard with information about the study and asked people whether or not they would be willing to meet a researcher. If they agreed, the researcher met with them and provided information about the study. If the participant provided written informed consent, the researcher assessed eligibility and collected baseline data. Baseline assessments were completed using a computer-assisted self-completion questionnaire. Following completion of baseline assessments, participants were randomised via an independent and remote telephone randomisation service by an independent Clinical Trials Unit using permuted blocks, stratified by site. Block size was randomly assigned between four and six. Equal numbers of participants were randomised to each arm of the trial. The researcher then notified the treating clinician which arm of the trial the participant was in.

The Sexual Health and Excessive Alcohol: Randomised trial (SHEAR) had two treatment conditions. Brief intervention comprised brief advice delivered by the treating clinician followed by input from an alcohol health worker (AHW) for those willing to receive it. Those randomised to control treatment received a general health information leaflet with advice about smoking, alcohol, diet and exercise. Brief advice from the treating clinician consisted of feedback on the possible health consequences of excessive alcohol consumption, written information about alcohol and health, and an offer of an appointment with an AHW. The appointment with the AHW lasted up to 30 minutes. In the case of any participant who was drinking at a harmful or dependent level, the AHW had the option of arranging a follow-up appointment or referring the participant to local alcohol services for individual alcohol counselling, detoxification or other treatments. Any participant who was unable to attend an appointment on the day was offered an appointment at a later date or the option of telephone-based information and advice.

After 6 months the participants were contacted by a researcher masked to the participant allocation status and asked to complete a telephone interview. Participants who completed the follow-up interview were offered a £15 honorarium in recognition of their time and any inconvenience related to their involvement in the study.

**Statistical methods**

The initial sample size calculation was based on identifying differences in mean weekly alcohol consumption found in our previous trial of brief intervention in an emergency department. In the first few months of the trial the rate of recruitment was higher than expected and the sample size was therefore increased to provide additional power to test both the primary and main secondary outcome: the proportion reporting unprotected sexual intercourse during the previous 3 months.

The final sample size was based on a practical size of 380 per arm (760 in total). If 65% of participants had unprotected sex in the control group compared with 50% in the intervention arm, the power to detect such an effect would be above 90%, assuming 25% drop-out, and a clustering design effect of 1.15.

**Results**

Eight hundred and two participants were recruited to the trial between August 2010 and May 2012, of whom 402 were randomised to brief intervention and 400 to control treatment. Participants had a median age of 27 years (interquartile range 24–30 years) and 432 (54%) were female. All but five participants in the active arm of the trial received brief advice from the treating clinician (n = 397, 99%). Of these, 81 participants (20%) also received input from an AHW.
Two hundred and ninety-one participants (72%) in the intervention arm and 301 participants (75%) in the control arm completed the follow-up interview. The participants allocated to the intervention arm were drinking 18.1 units per week and those allocated to the control arm were drinking 20.3 units per week. The adjusted mean difference in alcohol consumption between those in the active arm of the trial and those in the control group was therefore −2.33 units per week [95% confidence interval (CI) −4.69 to 0.03 units per week, \( p = 0.053 \)]. Unprotected sex was reported by 154 (53%) of those randomised to brief intervention and by 178 (59%) of those randomised to the control treatment (adjusted odds ratio 0.89, 95% CI 0.63 to 1.25, \( p = 0.496 \)). Participants randomised to brief intervention reported drinking a mean of 10.4 units of alcohol per drinking day compared with 9.3 units among the control group (a difference of 1.1 units, 95% CI 0.29 to 1.96 units, \( p = 0.009 \)). We did not find significant differences in any other secondary outcomes between each arm of the trial.

Mean costs per participant over 6 months were £319 among those randomised to brief intervention and £311 among those randomised to the control treatment. Although the additional cost of brief intervention was small compared with the total cost of care provided (£12.57, standard deviation £6.59), we did not find evidence to support the cost-effective use of this intervention.

**Conclusions**

We did not find evidence that brief intervention for excessive alcohol use among people attending sexual health clinics is associated with clinically important reductions in alcohol consumption or provides a cost-effective use of resources.

**Recommendations for future research**

1. Interventions for young people who present to sexual health services and drink at a level that may be harmful to their health should be developed and tested.
2. The impact that population-based strategies for reducing levels of alcohol misuse have on sexual health outcomes should be examined as part of wider efforts to assess their impact on health-related outcomes.

**Trial registration**

This trial is registered as ISRCTN 99963322.

**Funding**

Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research.
Health Technology Assessment

ISSN 1366-5278 (Print)
ISSN 2046-4924 (Online)

Five-year impact factor: 5.804

Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, The Cochrane Library and the ISI Science Citation Index and is assessed for inclusion in the Database of Abstracts of Reviews of Effects.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: nihredit@southampton.ac.uk

The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

Criteria for inclusion in the Health Technology Assessment journal

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: www.hta.ac.uk/

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 09/91/04. The contractual start date was in April 2011. The draft report began editorial review in April 2013 and was accepted for publication in January 2014. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2014. This work was produced by Crawford et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
Editor-in-Chief of Health Technology Assessment and NIHR Journals Library

Professor Tom Walley  Director, NIHR Evaluation, Trials and Studies and Director of the HTA Programme, UK

NIHR Journals Library Editors

Professor Ken Stein  Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andree Le May  Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck  Chair in Public Sector Management and Subject Leader (Management Group), Queen’s University Management School, Queen’s University Belfast, UK

Professor Aileen Clarke  Professor of Public Health and Health Services Research, Warwick Medical School, University of Warwick, UK

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Peter Davidson  Director of NETSCC, HTA, UK

Ms Tara Lamont  Scientific Advisor, NETSCC, UK

Professor Elaine McColl  Director, Newcastle Clinical Trials Unit, Institute of Health and Society, Newcastle University, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Professor of Health Sciences Research, Faculty of Education, University of Winchester, UK

Professor Jane Norman  Professor of Maternal and Fetal Health, University of Edinburgh, UK

Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professorial Research Associate, University College London, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Please visit the website for a list of members of the NIHR Journals Library Board: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: nihredit@southampton.ac.uk